Magnesium in Super-Refractory Status Epilepticus (SRSE)

What is Super-Refractory Status Epilepticus?

Mechanism of Action

• In prolonged seizures, GABA-A receptors are downregulated and internalized from the synapse
• Simultaneously, NMDA and AMPA (glutamate) receptors are upregulated
• This shift explains why benzodiazepines (which act on GABA-A) lose efficacy, while NMDA antagonists become particularly relevant
• Magnesium blocks the NMDA receptor channel pore in a voltage-dependent manner, reducing excitatory glutamatergic transmission
• This complements the mechanism of ketamine (another NMDA antagonist also used in SRSE)

Clinical Use and Dosing Protocol

Why it is Used in SRSE Specifically

1. Complementary mechanism - targets glutamate excitotoxicity, which is dominant in prolonged SE when GABAergic drugs have lost efficacy
2. Relative safety - compared to deep anesthetic agents (propofol, pentobarbital), magnesium carries lower risk of hemodynamic compromise at standard doses
3. Adjuvant to anesthetics - can be combined with ongoing anesthetic infusions to allow dose reduction
4. Potential neuroprotection - NMDA blockade may reduce excitotoxic neuronal injury in prolonged seizures
5. Specific utility in autoimmune SRSE - case series document benefit in NORSE (New Onset Refractory SE) and FIRES (Febrile Infection-Related Epilepsy Syndrome)

Adverse Effects / Contraindications

Place in the Therapeutic Algorithm

1. Repeat burst suppression
2. Additional non-anesthetic AEDs (e.g., topiramate, carbamazepine)
3. Ketamine (another NMDA antagonist, often preferred as first NMDA agent)
4. Pyridoxine (for pyridoxine-dependent SE)
5. Immunomodulation (steroids, IVIG, plasma exchange) for autoimmune causes
6. Ketogenic diet
7. Hypothermia, neurosurgery, or deep brain stimulation in extreme cases

Treatment of HSV Encephalitis

The Golden Rule: Start Empirically - Don't Wait

• Harrison's Principles of Internal Medicine 22E, p.1506

Diagnostic Approach (Flowchart)

1. Specific Antiviral Therapy

• Goldman-Cecil Medicine, p.3299
• Adams and Victor's Principles of Neurology 12e, p.451
• Katzung's Basic and Clinical Pharmacology 16e

2. When to Stop or Continue Acyclovir

• If CSF HSV PCR is positive: complete full 14-21 day IV course, then perform repeat LP to confirm PCR negativity before stopping
• If CSF is still PCR-positive at end of treatment: continue IV acyclovir with weekly PCR until negative
• If PCR is negative but clinical suspicion remains high (e.g., normal early CSF in first 24 hours, classic MRI pattern): continue acyclovir and repeat LP after 24-48 hours
• If PCR is negative and alternative diagnosis is established: acyclovir can be discontinued
• Immunocompromised patients: treat for at least 21 days; consider long-term oral suppression until CD4 >200

3. Mechanism of Acyclovir

• Harrison's Principles of Internal Medicine 22E, p.1506

4. Supportive Management

5. Corticosteroids - Controversial

• Significant cerebral edema with mass effect
• Post-HSE autoimmune encephalitis (see below): methylprednisolone 1 g IV daily for 5 days

6. Post-HSE Autoimmune Encephalitis - An Important Complication

• Relapse of symptoms (behavioral changes, movement disorders, seizures in children; delirium in adults)
• Worsening MRI findings
• Positive CSF/serum NMDA-receptor antibodies

• Goldman-Cecil Medicine, p.3306
• Adams and Victor's Principles of Neurology 12e, p.457

7. Relapses After Acyclovir

8. Acyclovir Side Effects to Monitor

• Adams and Victor's Principles of Neurology 12e, p.451

Prognosis

• Less than 20% return to work
• ~50% are classified as moderately to severely disabled
• Early treatment (before coma) is the strongest predictor of a good outcome - the level of consciousness at initiation of treatment is critical
• Goldman-Cecil Medicine, p.3304

Bacterial Meningitis: Management of Vancomycin + Ceftriaxone Resistance

Understanding the Problem

• Penicillin/cephalosporin resistance: alteration of penicillin-binding proteins (PBPs) by transformation and horizontal DNA transfer from related streptococci. Altered PBPs have lower affinity for beta-lactams, causing resistance ranging from intermediate to high level.
• Vancomycin penetration problem: even when S. pneumoniae is "susceptible" to vancomycin in vitro, dexamethasone (used adjunctively) reduces blood-brain barrier inflammation and thereby reduces CSF vancomycin penetration, potentially creating a pharmacokinetic failure even with a susceptible organism.

• Penicillin susceptible: MIC ≤0.06 μg/mL; resistant: ≥0.12 μg/mL
• Ceftriaxone/cefotaxime: MIC ≥1.0 μg/mL = high-level resistance
• Harrison's Principles of Internal Medicine 22E, p.1713

Step 1: Empirical Therapy (Before Culture/Sensitivities)

Do NOT reduce antibiotic doses as the patient improves - normalisation of the blood-brain barrier during recovery reduces achievable CSF levels.

• Harrison's Principles of Internal Medicine 22E, p.1762
• Rosen's Emergency Medicine, p.4407

Step 2: Targeted Therapy by Susceptibility Results

For S. pneumoniae:

• Goldman-Cecil Medicine, Table 381-6
• Rosen's Emergency Medicine, p.4411

Step 3: When Vancomycin + Ceftriaxone Fails - The Real Resistance Scenario

A. Add or Switch to Rifampicin

• Rifampicin (rifampin) penetrates the CSF excellently (unlike most antibiotics, it crosses even the uninflamed blood-brain barrier)
• Used as combination therapy - never monotherapy (rapid resistance emerges)
• Dose: 600 mg IV/PO every 24 h (up to 900 mg/day; 15 mg/kg/day in children)
• Combination: Vancomycin + Rifampicin is the standard salvage regimen for highly resistant pneumococcus
• Particularly important when dexamethasone is being used (rifampicin compensates for reduced vancomycin CSF levels)

B. Meropenem

• Carbapenem with excellent activity against penicillin-resistant S. pneumoniae, L. monocytogenes, H. influenzae, P. aeruginosa
• As effective as cefotaxime for pneumococcal, meningococcal, and H. influenzae meningitis
• Preferred over ceftriaxone for nosocomial/post-neurosurgical meningitis and for P. aeruginosa coverage
• Experimental data: meropenem was inferior to vancomycin but comparable to ceftriaxone in clearing pneumococcal CSF cultures
• Dose: 2 g IV every 8 h

C. Linezolid

• Dose: 600 mg IV every 12 h
• Used for cephalosporin-resistant pneumococcus in combination with vancomycin
• Also effective for MRSA meningitis (nosocomial/post-neurosurgical cases)
• Advantage: excellent CNS penetration; useful when beta-lactam allergy and vancomycin is needed

D. Moxifloxacin / Fluoroquinolones

• Moxifloxacin 400 mg IV/PO once daily
• Used with vancomycin for cephalosporin-resistant strains
• Levofloxacin is an alternative
• Caution: increasing fluoroquinolone resistance in some regions

E. Chloramphenicol

• Historical alternative; still useful in resource-limited settings or severe beta-lactam allergy
• Good CNS penetration
• Limitations: bacteriostatic (not bactericidal for pneumococcus at achievable CSF concentrations), bone marrow toxicity
• Goldman-Cecil Medicine, p.1916-1917
• Rosen's Emergency Medicine, p.4407-4411
• Adams and Victor's Principles of Neurology 12e, p.1881

Step 4: Pathogen-Specific Resistance Situations

N. meningitidis (Meningococcus)

• In the US, remains highly susceptible to penicillin and ampicillin
• Penicillin G or ampicillin is definitive therapy for susceptible strains
• Third-generation cephalosporins are used empirically and are effective

H. influenzae

• ~30% of isolates produce beta-lactamase (resistant to ampicillin/penicillin)
• Nearly all remain sensitive to third-generation cephalosporins
• For beta-lactamase-negative strains: ampicillin
• For resistant strains: ceftriaxone/cefotaxime (first-line), alternatives = chloramphenicol, cefepime, meropenem, fluoroquinolone, aztreonam

Nosocomial / Post-Neurosurgical Meningitis (MRSA, Coagulase-negative Staph, P. aeruginosa)

• Empirical: Vancomycin + Cefepime or Ceftazidime or Meropenem
• If beta-lactam contraindicated: linezolid (gram-positive) + aztreonam or ciprofloxacin (gram-negative coverage)

Listeria monocytogenes (cell-mediated immunity deficiency)

• Ampicillin ± gentamicin
• Trimethoprim-sulfamethoxazole if penicillin-allergic
• Cephalosporins have NO activity against Listeria - a critical point
• Stop dexamethasone if Listeria is confirmed (increased adverse outcomes shown in a prospective study)

The Dexamethasone Dilemma

• If using dexamethasone + vancomycin: consider adding rifampicin to ensure adequate CSF levels against resistant pneumococcus
• Discontinue dexamethasone if: organism is not S. pneumoniae or H. influenzae, or if Listeria is confirmed
• Dexamethasone benefit is only demonstrated in high-income countries - not shown in low-income settings
• Goldman-Cecil Medicine, p.1915

Key Principles of Antibiotic Use in Meningitis

1. IV route throughout - do not switch to oral; do not reduce doses as patient improves (BBB recovery reduces CSF levels)
2. CSF bactericidal levels should be 10-20x the minimal bactericidal concentration (MBC)
3. Rifampicin and chloramphenicol are the exceptions - they cross the uninflamed BBB; others require inflamed meninges for adequate penetration
4. Culture and sensitivity-guided de-escalation is mandatory - vancomycin should be stopped once susceptibility data allow
5. Antibiotic duration after organism identification: S. pneumoniae 10-14 days; N. meningitidis 7 days; H. influenzae 7 days; L. monocytogenes 21 days; gram-negative bacilli 21 days

• Goldman-Cecil Medicine, p.1902

Batten Disease (Neuronal Ceroid Lipofuscinoses - NCL)

1. Definition and Overview

• At least 13-14 subtypes have been identified (NCL1 through NCL14), each caused by a mutation in a distinct CLN gene
• The name "Batten disease" strictly refers to the juvenile form (CLN3), but is used colloquially for all NCL subtypes
• Incidence: approximately 2-4 per 100,000 children worldwide; collectively the most common pediatric neurodegenerative disease
• Almost universally fatal - most children die in childhood or early adulthood
• Adams and Victor's Principles of Neurology 12e, p.1952
• Harrison's Principles of Internal Medicine 22E, p.1407

2. Pathogenesis

Cellular Mechanism

• Each CLN gene encodes a protein critical to lysosomal function - either a lysosomal enzyme, a transmembrane protein, or a secretory protein
• When these proteins are deficient, undigested lipofuscin-like material accumulates in lysosomes, particularly in neurons
• The storage material consists of two pigmented lipids - ceroid and lipofuscin - which are cross-linked polymers of polyunsaturated fatty acids with the property of autofluorescence (important diagnostically)
• This accumulation triggers progressive neuronal death in the cerebral and cerebellar cortex (particularly granule cells and Purkinje cells)

Electron Microscopy Patterns (Ultrastructural Subtypes)

• Adams and Victor's Principles of Neurology 12e, p.1991

Inheritance

• Autosomal recessive: all infantile and juvenile forms (CLN1-3, CLN5-14)
• Autosomal dominant exception: CLN4 (Kufs disease, Parry type) - the only dominant NCL
• X-linked: not reported

3. Classification and Clinical Subtypes

CLN1 - Infantile NCL (Santavuori-Haltia Disease)

• Gene: PPT1 (palmitoyl-protein thioesterase 1)
• Onset: 3-18 months (after normal early development)
• Features:
  • Rapid psychomotor regression with ataxia, hypotonia
  • Widespread myoclonus
  • Retinal changes with extinction of the electroretinogram (ERG)
  • Progressive visual failure leading to blindness
  • EEG: slowing, spike-and-slow-wave, then eventually isoelectric record
  • Spastic quadriplegia, microcephaly
• Prognosis: death within a few years of onset

CLN2 - Late Infantile NCL (Jansky-Bielschowsky Disease) ⭐ Only FDA-Approved Treatment

• Gene: TPP1 (tripeptidyl peptidase 1)
• Onset: 2-4 years (after normal or slightly delayed development)
• Survival: typically 8-12 years of age
• Features (in roughly this order):
  1. Seizures (petit mal, grand mal) - usually the first sign
  2. Myoclonic jerks triggered by sensory stimuli (proprioception, voluntary movement, emotional excitement)
  3. Incoordination, tremor, ataxia, spastic weakness
  4. Lively tendon reflexes and Babinski signs
  5. Progressive mental deterioration → dementia → mutism
  6. Dysarthria, then complete loss of speech
  7. Visual failure (variable - may occur early due to rod-and-cone retinal degeneration)
  8. Wheelchair bound by late childhood
• Labs: vacuoles in 10-30% of circulating lymphocytes; azurophilic granules in neutrophils
• EEG: high-voltage spikes induced by photic stimulation (characteristic)
• Microcephaly: only in early-onset cases

CLN3 - Juvenile NCL (Batten Disease stricto sensu, Vogt-Spielmeyer Disease)

• Gene: CLN3 (encodes battenin, a lysosomal transmembrane protein)
• Onset: 4-10 years
• Survival: late teens to 20s-30s (longer course than other forms)
• Features (typically in this sequence):
  1. Visual loss - the hallmark first symptom (progressive pigmentary retinal degeneration)
  2. Seizures - appear later
  3. Ataxia
  4. Cognitive decline (behavioral changes, psychiatric symptoms - depression, anxiety, hallucinations)
  5. Progressive motor deterioration
• Ophthalmic findings: pigmentary retinopathy, bull's eye maculopathy, optic atrophy
• Vacuolated lymphocytes on peripheral blood smear - useful screening test

CLN4 - Adult NCL (Kufs Disease)

• Genes: CLN6 or DNAJC5 mutations (Parry type = autosomal dominant)
• Onset: adulthood (typically 3rd-4th decade)
• Features: two main phenotypes:
  • Type A: Progressive myoclonic epilepsy, cerebellar signs, dementia
  • Type B: Dementia, motor dysfunction, WITHOUT visual failure (retinal sparing is key - unlike other NCLs)
• No visual loss distinguishes it from other forms

CLN5 - Finnish Variant Late Infantile NCL

• Gene: CLN5
• Onset: 2-6 years
• Features: ataxia first, then psychomotor regression; unable to walk by age 10
• Visual loss (macular dystrophy, optic atrophy) between ages 6-10
• Most do not survive into their third decade

CLN6, CLN7, CLN8... (Other Forms)

• CLN6, CLN7, CLN8 present similarly to CLN2 (late infantile pattern) with variable onset and severity
• CLN14: rapidly progressing; intractable myoclonic seizures before age 2, rapid visual loss with optic atrophy

4. Summary Table

5. Pathology

Macroscopic

• Progressive brain atrophy - cerebral and cerebellar cortex
• Neuronal loss most severe in cortex

Microscopic

• Neuronal loss in cerebral and cerebellar cortices (granule cells and Purkinje cells)
• Curvilinear storage particles and osmophilic granules in remaining neurons
• Inclusions also found in:
  • Cutaneous nerve twigs
  • Endothelial cells of blood vessels
  • Peripheral blood lymphocytes (vacuoles) - diagnostic significance

Ultrastructure (Electron Microscopy)

• Characteristic inclusion body patterns per subtype (GROD, curvilinear, fingerprint - see above)
• Skin biopsy, conjunctival biopsy, or rectal mucosal biopsy can demonstrate inclusions diagnostically
• Adams and Victor's Principles of Neurology 12e, p.1991

6. Diagnosis

Clinical Suspicion

• Any child with the triad: seizures + progressive visual loss + cognitive/motor regression
• Peripheral blood smear showing vacuolated lymphocytes (CLN2, CLN3)

Diagnostic Workup

• Diagnosis is confirmed by gene sequencing in most cases

7. Treatment

A. Disease-Specific (Approved) Therapy

Cerliponase Alfa (Brineura) - CLN2 ONLY ⭐

• The ONLY FDA/EMA-approved disease-modifying treatment for any NCL
• A recombinant human TPP1 (enzyme replacement therapy - ERT)
• Restores TPP1 enzyme activity and breaks down the stored lipofuscin material
• Route: Intraventricular infusion via an indwelling intracerebroventricular (ICV) port (the first ERT approved for direct CNS delivery)
• Dose: Every 2 weeks, infused over several hours
• Indication: Slows loss of ambulation (walking/crawling) in pediatric patients with CLN2
• FDA 2017: Approved for symptomatic children ≥3 years
• FDA 2024 expanded approval: Now approved for children of all ages, including presymptomatic infants - allowing earlier intervention before symptom onset
• Clinical trial (NEJM 2018): Significantly reduced the rate of clinical decline compared to untreated historical controls
• Adverse effects: Many related to the ICV catheter placement (infection, device complications)
• Harrison's Principles of Internal Medicine 22E, p.1407
• NINDS/FDA 2024 update

B. Symptomatic Treatment

C. Emerging / Investigational Therapies

D. Supportive / Multidisciplinary Care

• Pediatric neurologist (seizure management, disease monitoring)
• Ophthalmologist (visual loss management, low-vision aids)
• Physiotherapist (mobility, spasticity, contractures)
• Speech-language therapist (communication, swallowing)
• Occupational therapist (daily living adaptations)
• Neuropsychologist / Psychiatrist (behavioral/psychiatric symptoms)
• Dietitian (nutritional management)
• Palliative care (as disease advances)
• Genetics (family counseling, prenatal diagnosis, carrier testing)
• Education: Individualized Education Plan (IEP) addressing vision impairment, seizures, learning difficulties

8. Differential Diagnosis

9. Prognosis

• CLN1 (infantile): death within a few years of onset
• CLN2 (late infantile): death at an average age of 8-12 years (without treatment)
• CLN3 (juvenile): survival into late teens to 30s (longest course)
• CLN4 (adult/Kufs): survival into adulthood, slower progression
• With cerliponase alfa (CLN2): significantly slowed functional decline; the disease trajectory is altered but not yet cured

Key Teaching Points

1. NCL/Batten disease = lysosomal storage disorder + neurodegeneration + autofluorescent lipofuscin accumulation
2. Triad: seizures + visual failure + dementia in a child = think NCL
3. Vacuolated lymphocytes on blood smear is a cheap bedside screening test
4. Electron microscopy of skin biopsy shows pathognomonic inclusion patterns
5. Only CLN2 has an approved disease-modifying therapy (cerliponase alfa/Brineura) - now approved from birth (2024 FDA expanded indication)
6. Gene therapy trials are active for CLN3, CLN5, and other subtypes and represent the best hope for future treatments
7. CLN4 (Kufs) is the only autosomal dominant form and the only form without visual loss

Batten Disease (NCL) - Complete Treatment Guide

PILLAR 1: Disease-Modifying Therapy (Approved)

Cerliponase Alfa (Brineura) - CLN2 Disease ONLY

Clinical Evidence

• Cerliponase alfa significantly slowed clinical decline vs historical untreated controls
• 24% achieved a Clinical Rating Scale score of 0-1 (near-normal function)
• Seizure rate: generalized tonic-clonic seizures in 41%, dystonia in 15%

Important Limitations

• Does NOT reverse vision loss - retinal degeneration continues even with ERT
• Not a cure - slows but does not stop disease progression
• CLN3 (the most common juvenile form, "classical Batten disease") is caused by a transmembrane protein defect - ERT cannot work for it because the protein cannot be delivered via the lysosomal pathway
• Adverse effects: pyrexia (60%), hypersensitivity reactions (82.6%), anaphylaxis (3%), infusion-associated reactions (18%), device/catheter-related complications

• Harrison's Principles of Internal Medicine 22E, p.1407
• Bradley and Daroff's Neurology in Clinical Practice, p.2632

PILLAR 2: Symptomatic Management

Seizure Management

Myoclonus

• Valproate + levetiracetam or clonazepam combination
• Piracetam (where available) has some evidence for action myoclonus

Spasticity

• Baclofen (oral or intrathecal pump in severe cases)
• Physiotherapy, orthoses, splinting
• Botulinum toxin for focal spasticity/dystonia

Behavioral and Psychiatric Symptoms (especially CLN3)

• SSRI antidepressants (fluoxetine, sertraline) for depression and anxiety
• Low-dose antipsychotics (risperidone, quetiapine) for hallucinations, agitation
• Behavioral management strategies through psychology
• CLN3 patients often develop significant psychiatric features in adolescence before severe physical decline

Sleep Disturbance

• Melatonin (widely used, good safety profile)
• Sleep hygiene measures
• Clonidine as second-line

Nutritional Support

• PEG tube (percutaneous gastrostomy) when swallowing deteriorates
• Nutritional supplementation to maintain weight
• Thickened fluids initially; eventually tube feeding is required
• Monitor for aspiration

Respiratory Management

• Chest physiotherapy and breathing exercises
• Management of recurrent aspiration pneumonia
• Non-invasive ventilation in late stages if appropriate (individualized decision)
• Advance directives and goals of care discussion

Visual Impairment

• Low-vision aids (magnifiers, high-contrast materials, screen readers)
• Orientation and mobility training
• Guide dogs for adolescents/adults (CLN3)
• No specific treatment halts retinal degeneration currently (even cerliponase alfa does not protect vision in CLN2)

PILLAR 3: Supportive / Multidisciplinary Care

Palliative Care

• Should be integrated early alongside curative/disease-modifying efforts - not just at end of life
• Goals of care: maximize quality of life, minimize suffering, support family
• Decisions about resuscitation, ventilation, and hospitalization should be discussed proactively with families

PILLAR 4: Emerging and Investigational Therapies (2024-2026 Pipeline)

A. Gene Therapy (AAV-Based) - Most Promising

• REGENXBIO halted RGX-181 (CNS) and RGX-381 (ocular) for CLN2
• Amicus Therapeutics returned CLN3 and CLN6 programs to Nationwide Children's Hospital

B. Antisense Oligonucleotides (ASO)

• FBF-001 (Zebronkysen) for CLN3: designed to skip the most common CLN3 mutation (1-kb deletion), restoring partial protein function
• N-of-2 compassionate use study commenced September 2024 - one of the most watched rare disease trials of 2025
• ASOs work by modifying RNA splicing, bypassing the mutation

C. Small Molecule Drugs

D. Stem Cell Therapy

• Neural stem cell transplantation: trials have been conducted for CLN1 and CLN2
• CNS access remains the primary barrier to effective delivery
• Results so far limited - transplanted cells do not integrate or migrate sufficiently
• Emerging: microglial cell replacement therapy - highlighted in a 2025 CNS Neuroscience & Therapeutics review (PMID 39925015) as particularly promising given the central role of microglial pathology in NCL

E. Combination Approaches

• Combining ERT (cerliponase alfa for CLN2) with ocular gene therapy (TTX-381) to address the separate retinal degeneration that ERT alone does not treat
• Combinations of gene therapy + immunosuppression to reduce AAV immune response

Why Treatment is Hard: The Core Challenges

1. CNS barrier: most drugs cannot reach the brain in therapeutic concentrations - hence ICV delivery for ERT
2. Genetic heterogeneity: 13+ subtypes, each needing a different molecular approach
3. Non-neuronal disease: bowel, cardiac, and other organ involvement also requires treatment
4. Late diagnosis: symptoms appear after significant neuronal loss has already occurred - making early (even presymptomatic) diagnosis and treatment critical
5. Membrane proteins vs soluble enzymes: ERT only works for soluble enzyme deficiencies (CLN2); membrane protein defects (CLN3) need gene therapy or other approaches
6. Commercial viability: multiple promising programs have been abandoned due to small patient populations and economics - a recurring tragedy in ultra-rare disease

Summary Table by Subtype

The bottom line: Cerliponase alfa (Brineura) is the only approved disease-modifying therapy and is restricted to CLN2. All other subtypes rely on symptomatic treatment. Gene therapy, ASOs, and small molecules represent the best hope for treating the remaining subtypes - with several programs in active Phase 1/2 trials as of 2025-2026.

Management and Treatment of ARDS

Berlin Definition (2012) - Quick Reminder

Key principle: ARDS is a syndrome, not a diagnosis. Always search for and treat the underlying cause. Most deaths in ARDS are from multi-organ failure, not hypoxemia itself.

General Principles of ICU Care

1. Identify and treat the underlying cause (pneumonia, sepsis, aspiration, pancreatitis, trauma)
2. Prophylaxis against VTE (DVT/PE)
3. Prophylaxis against GI bleeding (PPI/H2 blocker)
4. Minimize unnecessary procedures and their complications
5. Aspiration precautions (head-of-bed elevation 30-45°)
6. Prevent central line infections (aseptic technique, bundle care)
7. Minimize oversedation - daily awakening trials
8. Enteral nutrition as early as feasible (within 24-48 hours)
9. Prompt recognition and treatment of nosocomial infections

• Harrison's Principles of Internal Medicine 22E, p.2704

PILLAR 1: Lung-Protective Mechanical Ventilation (MOST IMPORTANT - MORTALITY BENEFIT PROVEN)

The ARDSNet Protocol

Why Use Predicted (Ideal) Body Weight?

• Males: 50 + 2.3 × (height in inches - 60)
• Females: 45.5 + 2.3 × (height in inches - 60)

Mechanisms of Ventilator-Induced Lung Injury (VILI) - What We're Preventing

1. Volutrauma - alveolar overdistention from excess tidal volume
2. Barotrauma - excess pressure injury
3. Atelectrauma - repeated alveolar collapse and reopening at end-expiration
4. Biotrauma - inflammatory mediator release from injured lung

• Barash Clinical Anesthesia 9e, p.570-574
• Harrison's Principles of Internal Medicine 22E, p.2711-2713

PILLAR 2: PEEP Management

2024 ATS Guideline Recommendations (Key Updates)

PEEP Titration Methods

• Empirical PEEP/FiO₂ tables (ARDSNet high PEEP or low PEEP tables) - most commonly used
• Esophageal pressure-guided PEEP (measures transpulmonary pressure) - especially useful in obese patients with stiff chest walls; a Phase 2 trial showed no benefit over empirical high PEEP-FiO₂ titration in unselected patients
• Electrical impedance tomography (EIT) - newer imaging-guided approach; a 2024 systematic review (PMID 38512400) shows promise for personalizing PEEP

Lung Recruitment Maneuvers (LRMs)

• Prolonged LRMs (e.g., sustained inflation at 40 cmH₂O for 40 seconds): Previously widely used; now strongly contraindicated by ATS 2024 - shown to increase mortality when combined with higher baseline PEEP (ART trial)
• Brief sigh breaths / stepwise LRMs: insufficient data; conditional use only
• The 2024 ATS guideline marks a paradigm shift away from LRMs

PILLAR 3: Prone Positioning

Evidence

When to Use

• PaO₂/FiO₂ <150 mmHg (P/F ratio ≤150) despite optimized ventilation
• Start early (within the first 36 hours) for best effect
• Duration: minimum 12-16 hours per day (PROSEVA used 16 h/day)
• Continue daily proning sessions until P/F ratio improves to >150 on supine position

Mechanism of Benefit

• Redistributes perfusion to now-ventilated (anterior) lung zones
• Recruits dorsal (dependent, previously atelectatic) lung units
• Makes lung inflation more homogeneous - reduces VILI
• Improves V/Q matching
• Facilitates secretion drainage

Contraindications / Complications

• Harrison's Principles of Internal Medicine 22E, p.2718-2719
• Barash Clinical Anesthesia 9e, p.576

PILLAR 4: Fluid Management

Conservative vs Liberal Fluid Strategy

• Same mortality but conservative fluid group had:
  • More ventilator-free days
  • More ICU-free days
  • Better oxygenation
  • Shorter ICU stay

Practical Approach

• Restrict IV fluids once the acute resuscitation phase is over (sepsis/shock)
• Use diuretics to reduce left atrial filling pressure if hemodynamically stable
• Target: minimize extravascular lung water while maintaining organ perfusion
• Balance: aggressive diuresis limited by hypotension and renal impairment
• Central venous monitoring to guide fluid decisions
• Harrison's Principles of Internal Medicine 22E, p.2727-2729

PILLAR 5: Neuromuscular Blockade (NMB)

Evidence

• ACURASYS trial (2010, French): Early cisatracurium infusion for 48h in severe ARDS (PaO₂/FiO₂ <150) improved 90-day mortality and ventilator-free days with low rates of critical illness myopathy
• ROSE trial (2019, NEJM): Did NOT confirm mortality benefit of routine NMB; however, control group received deep sedation (confounding factor)

2024 ATS Guideline

• Suggest use of neuromuscular blockers in early severe ARDS (conditional recommendation, low certainty)
• Prefer intermittent boluses over continuous infusion when possible
• Use continuous NMB infusion for: persistent ventilator dyssynchrony, need for deep sedation, prone positioning, or persistently high plateau pressures

Rationale for Use

• Eliminates patient-ventilator dyssynchrony (which causes high transpulmonary pressure spikes)
• May have direct anti-inflammatory effects via nicotinic receptor inhibition
• Enables fully lung-protective ventilation and safe prone positioning
• Agent: Cisatracurium preferred (not renally/hepatically metabolized)

Risk

• ICU-acquired weakness / critical illness myopathy - limit duration to 48h when possible
• Requires deeper sedation (use sedation + analgesia protocol)
• Harrison's Principles of Internal Medicine 22E, p.2732-2734
• Barash Clinical Anesthesia 9e, p.578

PILLAR 6: Corticosteroids

2024 ATS Guideline

• Suggest using systemic corticosteroids in mechanically ventilated ARDS patients (conditional recommendation, moderate certainty)

2026 Meta-Analysis Evidence

• Low-dose, short-course corticosteroids probably reduce short-term mortality in ARDS (RR 0.77, 95% CI 0.61-0.99; moderate certainty)
• Little to no increase in hospital-acquired infections or secondary pneumonia
• This is one of the strongest recent pieces of evidence supporting corticosteroid use

Practical Protocol

Note: Corticosteroids should NOT be started after day 14 of ARDS onset - possible harm

PILLAR 7: VV-ECMO (Venovenous Extracorporeal Membrane Oxygenation)

When to Consider

Evidence

• CESAR trial (UK): Referral to ECMO center improved 6-month survival without disability
• EOLIA trial (2018, NEJM): Initial ECMO vs standard care in severe ARDS - did not reach statistical significance for primary endpoint but showed a trend toward benefit; ECMO as rescue showed 40% crossover
• ATS 2024: Suggests VV-ECMO in selected patients with severe ARDS (conditional recommendation, low certainty)

Contraindications to VV-ECMO

• Injurious mechanical ventilation ≥7 days (lung recovery unlikely)
• Major pharmacologic immunosuppression
• Recent or expanding intracranial hemorrhage
• BMI >40-45 (technical difficulty)
• No realistic possibility of recovery or bridge to lung transplant
• Miller's Anesthesia 10e, Box 81.1

PILLAR 8: Sedation and Analgesia

• Analgesia-first approach (analgosedation) - treat pain before sedation
• Target light sedation (RASS -1 to 0) unless specific indications for deep sedation
• Daily spontaneous awakening trials (SAT) + spontaneous breathing trials (SBT) as soon as safe
• Deep sedation only for: NMB use, prone positioning, severe dyssynchrony, very high PEEP
• Avoid benzodiazepine infusions where possible - associated with worse delirium and outcomes
• Preferred agents: propofol or dexmedetomidine for sedation; fentanyl/morphine for analgesia

Additional/Adjuvant Measures

Management by Severity - Summary Algorithm

ALL ARDS:
├── Treat underlying cause
├── Lung-protective ventilation (VT 6 mL/kg PBW, Pplat ≤30, ΔP <15)
├── PEEP optimized per PEEP/FiO₂ table
├── Conservative fluid management
└── ICU bundle care (VTE, GI prophylaxis, nutrition, infection prevention)

MODERATE-SEVERE ARDS (P/F <200):
├── Higher PEEP strategy (NO prolonged recruitment maneuvers)
├── Corticosteroids (methylprednisolone)
└── Neuromuscular blockade (early, 48h) if dyssynchrony or refractory

SEVERE ARDS (P/F <150):
├── Prone positioning ≥16 h/day ← strong mortality benefit
├── Consider inhaled nitric oxide if pulmonary HTN or refractory hypoxemia
└── Refer for ECMO if failing all the above

REFRACTORY SEVERE ARDS:
└── VV-ECMO (rescue therapy)

What Does NOT Work in ARDS

Prognosis and Outcomes

• Mortality has fallen from ~60% in the 1980s to <40% currently
• Most deaths are from multi-organ failure, not refractory hypoxemia
• Survivors frequently experience:
  • Physical impairment (muscle weakness, fatigue)
  • Cognitive impairment (memory, executive function)
  • Psychiatric sequelae (PTSD, depression, anxiety) - "Post-ICU Syndrome"
  • Reduced quality of life persisting 5+ years after discharge
• Murray and Nadel's Respiratory Medicine, p.3666
• Harrison's Principles of Internal Medicine 22E, p.2694